An interventional study of Ventilator derived positive pressure ventilation - V-PPV and T-piece resuscitator (TPR) in Neonatal Resuscitation and Apnea Neonatal, sponsored by Michelle Baczynski. Recruiting at 11 sites in 3 countries. Open to participants aged 25 Weeks to 29 Weeks. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Michelle Baczynski · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Premature Birth with a site in Canada — 26 open to participants now, 34 under way, 2 of them phase 3. Premature Birth · Canada.
Among the 139 studies in Premature Birth with a site in Canada, this one is the 16th largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2025, is one of 65 with no phase, reaches primary completion later than 27 of the 33 other live ones, and was the 127th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →26 of the 139 studies in Premature Birth with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Women only
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages up to 29 wk
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 28 wk–32 wk
Hamilton Health Sciences Corporation · Sites in Canada
Ages up to 28 wk
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 25 Weeks to 29 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 17 · Phase 4 5
First in 1998; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 780 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 80 across the 106 interventional studies, 144 across the 33 observational. Of the 78 that completed or were terminated, 9 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 139 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Michelle Baczynski as lead sponsor.
Michelle Baczynski has 1 study filed under Premature Birth — fewer than ten, so there is no comparison to draw.
5 of the studies in Premature Birth with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05114096McMaster UniversitySingle Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) | 2026-12-31 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07732257McGill University Health Centre/Research Institute of the McGill University Health CentreWireless MicroPremVitals Button Sensor in the NICU | 2027-01-30 |
| NCT05213806IWK Health CentreWithHolding Enteral Feeds Around Blood Transfusion (International) | 2027-03-31 |
| NCT07262385University of British ColumbiaCalmer Brains in Very Preterm Infants | 2027-04 |
Add all 5 to your calendar (.ics) → With an account.
Among the 139 studies in Premature Birth with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many extremely premature infants require immediate help with breathing after birth. Positive pressure ventilation (PPV) using a device called a T-piece resuscitator is a common method. PPV is needed to establish proper lung function, improve gas exchange, and encourage the infant to breathe spontaneously. However, T-piece resuscitators have limitations, like a lack of visual feedback and variable settings, which may result in reduced effectiveness of PPV. Improving PPV effectiveness may reduce the need for more invasive procedures, such as intubation, which pose an increased risk of complications and death for these fragile infants. A novel approach, that may overcome the above limitations and deliver PPV with precise settings through a nasal mask, is to use a ventilator to deliver PPV (V-PPV) using a respiratory mode called nasal intermittent positive pressure ventilation (NIPPV). While NIPPV is commonly used in neonatal intensive care units to support breathing in premature infants, the impact of V-PPV use during immediate post-birth stabilization needs to be studied. Preliminary data from our recent single-center study confirmed the feasibility of using V-PPV for resuscitation of extremely premature babies and indicated its potential superiority with a 28% decrease in the need for intubation compared to historical use of T-piece. This promising innovation may enhance outcomes for these vulnerable infants by refining the way we provide respiratory support in their critical first moments. The research objective is to compare the clinical outcomes of extremely premature infants receiving manual T-piece versus V-PPV during immediate post-birth stabilization. The primary aim is to evaluate the impact of V-PPV on major health complications or death. This study seeks to provide insights into improving the care and outcomes of these infants during a critical stage of transition from fetus to newborn.
Inclusion Criteria::
Exclusion Criteria:
Positive pressure ventilation during the first 10 minutes after birth will be provided with a T-Piece Resuscitator (TPR; Neopuff, Fisher \& Paykel Healthcare) connected to an appropriately sized face-mask, with settings adjustable within specified ranges for positive inspiratory pressure, positive end expiratory pressure, and fraction of inspired oxygen based on local policy. These specified ranges will be standardized across sites.
Device: T-piece resuscitator (TPR)
Positive pressure ventilation (PPV) during the first 10 minutes after birth will be provided using a neonatal ventilator set up in noninvasive positive pressure ventilation (NIPPV) mode, connected to an appropriately sized nasal mask or prongs and a dual limb neonatal ventilator circuit, with settings adjustable within specified ranges for positive inspiratory pressure, positive end expiratory pressure, respiratory rate and inspiratory time and fraction of inspired oxygen based on local policy. These specified ranges will be standardized across sites.
Device: Ventilator derived positive pressure ventilation - V-PPV
The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. Ventilator delivered positive pressure ventilation (V-PPV) using a nasal interface will be delivered to the infant in the resuscitation room.
The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. PPV will be provided with a T-piece resuscitator (Neopuff, Fisher \& Paykel Healthcare) connected to an appropriately sized face-mask.
Composite of pre-discharge mortality
Death in NICU
Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)
Major neuro-injury
Defined as IVH ≥grade 3, cerebellar hemorrhage or periventricular leukomalacia.
Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)
Moderate-severe BPD
Defined as 2 L/min nasal cannula or other forms of non-invasive ventilation support or invasive mechanical ventilation.
Time frame: At 36 weeks' postmenstrual age.
Components of the primary outcome
Pre-discharge mortality, major neuro-injury or moderate-severe BPD
Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)
Frequency of receipt of advanced cardiopulmonary resuscitation measures
Chest compressions or epinephrine administration for the purpose of resuscitation.
Time frame: From enrollment to 1 hour post intervention.
Duration of invasive mechanical ventilation during NICU admission
Total number of days on invasive mechanical ventilation
Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)
Discharge on home oxygen
Discharge from the NICU requiring oxygen support at home
Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)
Other relevant key prematurity related adverse outcome
Necrotizing enterocolitis ≥ stage 2a, retinopathy of prematurity needing treatment.
Time frame: From enrollment through study completion (up to 50 weeks postmenstrual age)
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Sep 2028, 33 months after the start.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 33 months is above that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.